Caplin Point Laboratories マネジメント

マネジメント基準チェック /44

Caplin Point Laboratoriesの CEO はSridhar Ganesanで、 Mar2015年に任命され、の在任期間は 9.67年です。の年間総報酬は₹ 9.30Mで、 95.7%給与と4.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.13%を直接所有しており、その価値は₹ 195.26M 。経営陣と取締役会の平均在任期間はそれぞれ8.8年と3.4年です。

主要情報

Sridhar Ganesan

最高経営責任者

₹9.3m

報酬総額

CEO給与比率	95.7%
CEO在任期間	9.7yrs
CEOの所有権	0.1%
経営陣の平均在職期間	8.8yrs
取締役会の平均在任期間	3.4yrs

経営陣の近況

Recent updates

CEO報酬分析

Caplin Point Laboratories の収益と比較して、Sridhar Ganesan の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	₹5b
Jun 30 2024	n/a	n/a	₹5b
Mar 31 2024	₹9m	₹9m	₹5b
Dec 31 2023	n/a	n/a	₹4b
Sep 30 2023	n/a	n/a	₹4b
Jun 30 2023	n/a	n/a	₹4b
Mar 31 2023	₹9m	₹8m	₹4b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹3b
Jun 30 2022	n/a	n/a	₹3b
Mar 31 2022	₹6m	₹5m	₹3b
Dec 31 2021	n/a	n/a	₹3b
Sep 30 2021	n/a	n/a	₹3b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹6m	₹5m	₹2b
Dec 31 2020	n/a	n/a	₹2b
Sep 30 2020	n/a	n/a	₹2b
Jun 30 2020	n/a	n/a	₹2b
Mar 31 2020	₹6m	₹6m	₹2b
Dec 31 2019	n/a	n/a	₹2b
Sep 30 2019	n/a	n/a	₹2b
Jun 30 2019	n/a	n/a	₹2b
Mar 31 2019	₹6m	₹6m	₹2b
Dec 31 2018	n/a	n/a	₹2b
Sep 30 2018	n/a	n/a	₹2b
Jun 30 2018	n/a	n/a	₹1b
Mar 31 2018	₹6m	₹6m	₹1b

報酬と市場: Sridharの総報酬 ($USD 110.35K ) は、 Indian市場 ($USD 481.61K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Sridharの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sridhar Ganesan (69 yo)

9.7yrs

在職期間

₹9,300,000

報酬

Dr. Sridhar Ganesan has been the Managing Director of Caplin Point Laboratories Ltd since March 28, 2015. Dr. Ganesan has been Whole Time Director of Caplin Point Laboratories Ltd since August 25, 2014. He...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sridhar Ganesan	MD & Whole Time Director	9.7yrs	₹9.30m	0.13% ₹ 195.3m
D. Muralidharan	Chief Financial Officer	8.8yrs	₹9.10m	0.020% ₹ 30.0m
Partheeban Siddarth	Chief Operating Officer	13.3yrs	₹1.90m	11.84% ₹ 17.8b
G. Venkatram	General Counsel	2.3yrs	₹6.50m	データなし
M. Narayanan	Deputy Chief Financial Officer	no data	データなし	データなし
Ashok Partheeban	Head of Marketing - Latam Business	no data	データなし	11.91% ₹ 17.9b
Thiagaraja Manikandan	Chief Transformation & Digital Officer	less than a year	データなし	データなし

8.8yrs

平均在職期間

経験豊富な経営陣: 524742の経営陣は経験豊富で経験豊富です（平均在職期間は8.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Sridhar Ganesan	MD & Whole Time Director	10.8yrs	₹9.30m	0.13% ₹ 195.3m
Paarthipan Chellappan	Non-Executive Non-Independent Chairman	34.6yrs	データなし	18.64% ₹ 28.0b
Chanderkanta Gariyali	Non-Executive Independent Director	4.7yrs	₹140.00k	データなし
R. Nagendran	Non-Executive Independent Director	2.2yrs	₹160.00k	データなし
S. Deenadayalan	Independent Non-Executive Director	2.2yrs	₹180.00k	0.000090% ₹ 135.3k
R. Vijayaraghavan	Independent Director	less than a year	データなし	データなし

3.4yrs

平均在職期間

72yo

平均年齢

経験豊富なボード: 524742の取締役会は経験豊富であると考えられます ( 3.4年の平均在任期間)。

Caplin Point Laboratories マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Caplin Point Laboratories Limited Announces Cessation of D Sathyanarayanan as an Independent Director

Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer

Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023

Caplin Point Laboratories Limited Announces Change in Directorate

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Recent updates

Caplin Point Laboratories Limited Announces Cessation of D Sathyanarayanan as an Independent Director

Second quarter 2025 earnings released: EPS: ₹17.22 (vs ₹15.13 in 2Q 2024)

Caplin Point Laboratories Limited to Report Q2, 2025 Results on Nov 07, 2024

Price target increased by 14% to ₹2,142

Upcoming dividend of ₹2.50 per share

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 18%

Price target increased by 17% to ₹1,717

Dividend of ₹2.50 announced

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024

Caplin Point Laboratories Limited to Report Q1, 2025 Results on Aug 07, 2024

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer

Investor sentiment improves as stock rises 17%

Full year 2024 earnings: Revenues in line with analyst expectations

Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited to Report Fiscal Year 2024 Results on May 16, 2024

Third quarter 2024 earnings released: EPS: ₹15.44 (vs ₹12.86 in 3Q 2023)

Caplin Point Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024

Investor sentiment improves as stock rises 17%

Price target increased by 8.0% to ₹1,076

Second quarter 2024 earnings released: EPS: ₹15.13 (vs ₹12.09 in 2Q 2023)

Caplin Point Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023

Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023

Upcoming dividend of ₹2.50 per share at 0.5% yield

Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023

Consensus EPS estimates increase by 12%

Investor sentiment improves as stock rises 15%

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

First quarter 2024 earnings released: EPS: ₹13.62 (vs ₹11.21 in 1Q 2023)

Caplin Point Laboratories Limited to Report Q1, 2024 Results on Aug 07, 2023

Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP

Consensus EPS estimates increase by 12%

Upcoming dividend of ₹2.00 per share at 0.3% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Caplin Point Laboratories Limited to Report Q4, 2023 Results on May 24, 2023

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: ₹12.86 (vs ₹9.90 in 3Q 2022)

Caplin Point Laboratories Limited to Report Q3, 2023 Results on Feb 11, 2023

Price target increased to ₹948

Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)

Caplin Point Laboratories Limited (BSE:524742) acquired API plant in Vizag from Metrochem API Private Limited.

Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)

Caplin Point Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022

Caplin Point Laboratories Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited Announces Change in Directorate

Upcoming dividend of ₹2.00 per share

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released: EPS: ₹11.21 (vs ₹9.37 in 1Q 2022)

Caplin Point Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Caplin Point Laboratories Limited Announces Resignation of D P Mishra as Non-Executive, Non-Independent Director

Investor sentiment improved over the past week

Upcoming dividend of ₹2.00 per share

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Caplin Point Laboratories Limited Approves Interim Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited to Report Fiscal Year 2022 Results on May 12, 2022

Insufficient new directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Caplin Point Laboratories Limited to Report Q3, 2022 Results on Feb 03, 2022

Insufficient new directors

Insider recently sold ₹4.3m worth of stock

Second quarter 2022 earnings released: EPS ₹9.91 (vs ₹7.52 in 2Q 2021)

Upcoming dividend of ₹1.50 per share

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS ₹9.37 (vs ₹7.21 in 1Q 2021)

Investor sentiment improved over the past week

マネジメント基準チェック /44